Regeneron's preventative anitbody could be valuabl
Post# of 144904
![](/assets/46931549/no_avatar_available_thumb.jpg)
" Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient"
https://investor.regeneron.com/news-releases/...prevention
It is an antibody cocktail, which by its very nature will be short lived.
An effective vaccine will be more likely to induce sustained immunity.
I would be more concerned with treatments that address the immune dysfunction of covid (Humanigen's lenzilumab), that could prove effective.
As has been said recurrently, Leronlimab appears to be in a class by itself. Positive trial results will render these discussions moot.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)